Hansa Biopharma
Hansa Biopharma is a commercial-stage biopharmaceutical company developing and commercializing immunomodulatory treatments for people with rare immunological conditions. Founded in 2007 and headquartered in Lund, Sweden, it uses a proprietary antibody-cleaving enzyme platform to target pathogenic IgG antibodies. Its mission is to transform care for patients with acute or complex immune disorders through novel therapies, with operations across Europe and the United States.
